FLEX NEOADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from FLEX

Evidence / Neoadjuvant / FLEX
The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis
Publication: ESMO Breast Cancer 2025 Authors: Brufsky, et al. Title: The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis Background: The BluePrint (BP), 80-gene signature, provides insight into the intrinsic subtype of early-stage breast cancer (EBC). This study evaluates Read More
Real World Evidence of MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting
Publication: ASBRS 2025 Authors: Thompson et al. Title: Real World Evidence of MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting Introduction: Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and Read More
Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX
Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce OโShaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrintยฎ Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: โข Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision MedicineโBiology Is Still King
Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce OโShaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision MedicineโBiology Is Still King Abtract: Clinical Read More
MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Source: San Antonio Breast Cancer Symposiumยฎ Authors: Joyce OโShaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigatorsโ Group Title: MammaPrintยฎ and BluePrintยฎ Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Read More
Improved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read More